EMA601: Preclinical development of the humanized anti-GPVI Fab published in the European Heart Journal. A safe lead candidate with unprecedented anti-thrombotic and anti-thrombo-inflammatory potency
Eibelstadt/Würzburg, Germany – 16 August 2024
EMFRET Analytics announces the publication of new research on its humanized anti-platelet glycoprotein VI (GPVI) Fab fragment EMA601 in the European Heart Journal. The study, conducted in collaboration with researchers at Julius-Maximilians-Universität Würzburg (JMU) and the University Hospital Würzburg (UKW), highlights EMA601 as an exceptionally potent GPVI inhibitor with a highly favorable safety profile.
GPVI is a validated target for antithrombotic therapy. In preclinical models, EMA601 demonstrated markedly higher potency than previously described GPVI-targeting approaches, efficiently preventing arterial thrombosis and protecting from ischemic stroke while preserving normal hemostasis.
The results position EMA601 as a next-generation GPVI inhibitor and a promising lead candidate for clinical development, combining strong antithrombotic efficacy with minimal bleeding risk. The work underscores the translational potential of EMA601 and highlights the productive collaboration between EMFRET Analytics and cardiovascular researchers at JMU/UKW advancing innovative therapies targeting platelet-driven thrombo-inflammatory disease. The article
